Pharmalot -- Already one of the most vulnerable big drugmakers to patent expirations, Eli Lilly was dealt a serious blow late yesterday when a federal judge invalidated a method-of-use patent on its Strattera ADHD pill. The upshot means that a slew of generic pills from Teva Pharmaceutical and Sandoz, among others, are now expected to appear imminently, instead of in 2017.
